1. Effect of Pexelizumab in Coronary Artery Bypass Graft Surgery With Extended Aortic Cross-Clamp Time 
Peter K. Smith, MD, Michel Carrier, MD, John C. Chen, MD, Axel Haverich, MD, Jerrold H. Levy, MD, Philippe Menasché, MD, Stanton K. Shernan, MD, Frans Van de Werf, MD, PhD, Peter X. Adams, MD, Thomas G. Todaro, MD, Edward Verrier, MD 
The Annals of Thoracic Surgery 
Volume 82, Issue 3, Pages (September 2006)
DOI: /j.athoracsur
Copyright © 2006 The Society of Thoracic Surgeons Terms and Conditions

2. Fig 1
Treatment-independent effect of cross-clamp time on peak postoperative CK-MB levels. Plots show the peak CK-MB levels across the population for patients cross-clamped. (A) less than 30 minutes, (B) 30 to 90 minutes, and (C) 90 or greater minutes. Note: CK-MB data were available for 2,984 patients. (CK-MB = creatine kinase-myocardial band.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2006 The Society of Thoracic Surgeons Terms and Conditions

3. Fig 2
Mortality by aortic cross-clamp time. Data shown are for day 30 mortality (□) and mean peak CK-MB release (♦) across various cross-clamp intervals for patients in the current analysis. (CK-MB = creatine kinase-myocardial band.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2006 The Society of Thoracic Surgeons Terms and Conditions

4. Fig 3
Effect of treatment on the distribution of peak CK-MB levels. Distribution plots of peak postoperative CK-MB levels shown are for populations requiring the following cross-clamp time: (A) less than 30 minutes (x = placebo [n =177]; o = Pexelizumab [n = 171]), (B) 30 to 90 minutes (x = placebo [n = 999]; o = Pexelizumab [n = 1,013], and (C) 90 or greater minutes (x = placebo [n = 309]; o = Pexelizumab [n= 315]). (p values shown are for the log-rank analysis; CK-MB = creatine kinase-myocardial band.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2006 The Society of Thoracic Surgeons Terms and Conditions

5. Fig 4
Effect of Pexelizumab on mean peak CK-MB levels according to cross-clamp time. Data shown are mean values ± standard error for (A) the overall population and (B) patients with two or more risk factors. (*p < 0.05 compared with placebo; ■ = placebo; □ = Pexelizumab.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2006 The Society of Thoracic Surgeons Terms and Conditions

6. Fig 5
Effect of Pexelizumab on death-MI according to cross-clamp time. Data shown are mean values ± standard error for (A) the overall population and (B) patients with two or more risk factors. (*p < 0.05 compared with placebo; ■ = placebo; □ = Pexelizumab; MI = myocardial infarction.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2006 The Society of Thoracic Surgeons Terms and Conditions

7. Fig 6
Effect of Pexelizumab on death according to cross-clamp time. Data shown are mean values ± standard error for (A) death for the overall population, and (B) death for patients with two or more risk factors. (*p < 0.05 compared with placebo; ■ = placebo; □ = Pexelizumab.)
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2006 The Society of Thoracic Surgeons Terms and Conditions

8. Fig 7
Kaplan-Meier survival curves showing the effect of Pexelizumab on survival in patients requiring 90 or greater minutes of cross-clamp time. Data shown are for (A) the overall population and (B) patients with two or more risk factors. The p values are for the log-rank analysis of the curves.
The Annals of Thoracic Surgery  , DOI: ( /j.athoracsur )
Copyright © 2006 The Society of Thoracic Surgeons Terms and Conditions